BIIB Biogen Inc. - Common Stock
$218,71
Precio · Ago 19, 2026
Fundamentales a fecha de Jul 29, 2026
Rango 52S
$132–$220
98% of range
Calificación del Analista
BUY
43 analysts
Precio Objetivo
$236
+8% upside
P/E (TTM)
29.1
ROE
7.2%
Margen de Beneficio Neto
13.1%
Acerca de Biogen Inc. - Common Stock Descripción general de la empresa de Wikipedia
Biogen Inc. es una empresa biotecnológica multinacional estadounidense con sede en Cambridge, Massachusetts, especializada en el descubrimiento, desarrollo y suministro de terapias para el tratamiento de enfermedades neurológicas a pacientes de todo el mundo.
Leer más
Biogen Inc. es una empresa biotecnológica multinacional estadounidense con sede en Cambridge, Massachusetts, especializada en el descubrimiento, desarrollo y suministro de terapias para el tratamiento de enfermedades neurológicas a pacientes de todo el mundo.
## Historia
Fue fundada en 1978 en Ginebra con el nombre de Biotechnology Geneva por varios biólogos destacados, entre los que se encontraban Kenneth Murray, de la Universidad de Edimburgo, Phillip Allen Sharp, del Instituto Tecnológico de Massachusetts, Walter Gilbert, de Harvard (que ejerció de director general durante la fase inicial), Heinz Schaller, de la Universidad de Heidelberg, y Charles Weissmann, de la Universidad de Zúrich (que aportó el primer producto, el interferón alfa). Posteriormente, Gilbert y Sharp fueron galardonados con los premios Nobel: Gilbert fue reconocido en 1980 con el Premio Nobel de Química por su trabajo en la comprensión de la secuenciación del ADN, mientras que Sharp recibió el Premio Nobel de Fisiología o Medicina en 1993 por su descubrimiento de los genes divididos.
En 2003 se fusionó con IDEC Pharmaceuticals, con sede en San Diego (formada en 1985 por los médicos e inmunólogos de la Universidad de California-San Diego Ivor Royston y Robert E. Sobol, el bioempresario de San Diego Howard Birndorf y los investigadores del cáncer de la Universidad de Stanford Ron Levy y Richard Miller) y adoptó el nombre de Biogen Idec.
A raíz de los cambios en las áreas centrales de investigación, la empresa ha acortado su nombre, pasando a llamarse simplemente Biogen. Las acciones de Biogen forman parte de varios índices bursátiles, como el S&P 100, el S&P 500, el S&P 1500 y el NASDAQ-100, y la empresa cotiza en la bolsa de valores NASDAQ con el símbolo BIIB.
En mayo de 2006, la empresa anunció que adquiriría el especialista en cáncer Conforma Therapeutics por 250 millones de dólares. Más tarde, ese mismo mes, la empresa anunció su intención de adquirir Fumapharm AG, consolidando la propiedad de Fumaderm y BG-12, un fumarato oral, que se está estudiando para el tratamiento de la esclerosis múltiple y la psoriasis.
En enero de 2007, la empresa anunció que adquiriría Syntonix Pharmaceuticals por un máximo de 120 millones de dólares, con lo que obtendría el principal producto de Syntonix para la hemofilia B, así como la tecnología para desarrollar tratamientos inhalables.
En 2007, la empresa llegó a un acuerdo de licencia con Neurimmune, una empresa derivada de la Universidad de Zúrich, para el medicamento contra la enfermedad de Alzheimer Aducanumab, desarrollado por esta empresa suiza. Posteriormente, Neurimmune vendió sus derechos de licencia por 200 millones de dólares a Biogen.
En febrero de 2013, Bloomberg publicó la noticia de que Biogen planeaba pagar a Elan 3.250 millones de dólares por los derechos completos de Tysabri, utilizado para tratar la esclerosis múltiple.
En enero de 2015, la empresa anunció que adquiriría Convergence Pharmaceuticals por un máximo de 675 millones de dólares, con el objetivo de acelerar el desarrollo de la cartera de productos de Convergence, en particular CNV1014802 - una molécula pequeña de fase II candidata a bloquear los canales de sodio. En octubre de 2015, la empresa anunció que despediría al 11% de su plantilla, con efecto inmediato.
En marzo de 2019, la empresa anunció que adquiriría Nightstar Therapeutics por 25,50 dólares por acción (800 millones de dólares en total). Nightstar se centra en las terapias genéticas basadas en virus adeno-asociados para los trastornos hereditarios de la retina. Con un revés en su investigación de fármacos para el alzheimer, en marzo de 2019 las acciones de Biogen cayeron bruscamente. Terminó el ensayo de su fármaco aducanumab, que estaba fabricando junto con Eisai. En octubre de 2019, sin embargo, anunciaron que buscarían la aprobación de la FDA para aducanumab junto con Eisai.
En febrero de 2020, Biogen y Sangamo Therapeutics anunciaron un acuerdo de licencia global para desarrollar compuestos para enfermedades neuromusculares y neurológicas.
En mayo de 2020, la empresa concluyó la construcción de una instalación de última generación en Solothurn (Suiza), que producirá el medicamento contra el Alzheimer aducanumab a finales de 2021, junto con su planta de fabricación de Carolina del Norte. El anticuerpo monoclonal, codesarrollado con Eisai, atrajo un considerable interés de los inversores en biotecnología cuando Berkshire Hathaway, de Warren Buffett, compró 648 447 acciones de Biogen por un valor combinado de 192,4 millones de dólares.
En septiembre de 2020, Biogen Inc. realizó un depósito de 10 millones de dólares en OneUnited Bank para proporcionar más capital para financiar préstamos para viviendas y desarrollo comercial en las comunidades negras. En noviembre, la empresa anunció que adquiriría una participación de 650 millones de dólares en Sage Therapeutics y realizaría un pago inicial de 875 millones de dólares, con el fin de desarrollar conjuntamente una serie de tratamientos contra la depresión.
Para el año fiscal 2017, la empresa reportó ganancias de
2539 millones de dólares, con un ingreso anual de 12274 millones de dólares, un aumento del 7,2 % con respecto al ciclo fiscal anterior. Las acciones de Biogen cotizan a más de 289 dólares por acción, y su capitalización bursátil estaba valorada en más de 63000 millones de dólares en noviembre de 2018. La empresa ocupó el puesto 245 en la lista Fortune 500 de 2018 de las mayores empresas de Estados Unidos por ingresos.
== Referencias ==
Fuente: Wikipedia, CC BY-SA 4.0 · Ver en Wikipedia ↗
BIIB Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$218.71
Capitalización Bursátil
$37.49B
P/E (TTM)
29.1
BPA (TTM)
$8.79
Ingresos (TTM)
$9.89B
Rendimiento div.
—
ROE
7.2%
Deuda/Capital
—
Rango 52S
$132 – $220
BIIB Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$9.89B
2016-12-31
→
2025-12-31
BPA
$8.79
2016-12-31
→
2025-12-31
Flujo de caja libre
$2.05B
2016-12-31
→
2025-12-31
Márgenes
13.1%
2016-12-31
→
2020-12-31
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
BIIB
Mediana de Pares
P/E (TTM)
29.1
17.7
P/S (TTM) (P/V (TTM))
3.8
6.8
P/B (P/C)
2.1
6.4
Price / FCF (Precio / FCF)
18.3
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
BIIB
Mediana de Pares
Net Profit Margin (Margen de Beneficio Neto)
13.1%
20.3%
ROA
4.5%
11.4%
ROE
7.2%
16.8%
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
BIIB
Mediana de Pares
Current Ratio (Ratio corriente)
2.7
3.4
Quick Ratio (Ratio Rápido)
0.4
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
BIIB
Mediana de Pares
Revenue YoY (Ingresos interanuales)
2.2%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
-0.94%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
-6.0%
—
EPS YoY (EPS interanual)
-21.4%
—
Net Income YoY (Beneficio Neto interanual)
-20.8%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
BIIB
Mediana de Pares
BIIB Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
43 analistas
- Compra fuerte 9 20,9%
- Compra 20 46,5%
- Mantener 13 30,2%
- Venta 1 2,3%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
31 analistas · 2026-08-13
Mediana
$237.00
Ahora
$218.71
Mín
$165.00
Máx
$300.00
Objetivo mediano
$237.00
+8,4%
Objetivo medio
$235.57
+7,7%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
0.75%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $3.60 | $3.01 | 0.59% |
| 31 de marzo de 2026 | $3.57 | $2.83 | 0.74% |
| 31 de diciembre de 2025 | $1.99 | $1.65 | 0.34% |
| 30 de septiembre de 2025 | $4.81 | $3.96 | 0.85% |
| 30 de junio de 2025 | $5.47 | $3.94 | 1.5% |
| 31 de marzo de 2025 | $3.02 | $2.58 | 0.44% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| RVMD | — | — | — | — | — | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B | $10.76B | $9.70B | |
| Cost of Revenue | $2.40B | $2.31B | $2.53B | $2.28B | $2.11B | $1.81B | $1.96B | $1.82B | $1.63B | $1.48B | $1.24B | $1.17B | |
| Gross Profit | · | · | · | · | · | $11.64B | $12.42B | $11.64B | $10.64B | $9.97B | $9.52B | $8.53B | |
| SG&A Expense | $2.43B | $2.40B | $2.55B | $2.40B | $2.67B | $2.50B | $2.37B | $2.11B | $1.93B | $1.95B | $2.11B | $2.23B | |
| Operating Expenses | $8.33B | $7.77B | $8.54B | $6.58B | $9.24B | $8.40B | $7.34B | $7.56B | $6.93B | $6.30B | $5.87B | $5.75B | |
| Operating Income | · | · | · | · | $2.84B | $4.55B | $7.04B | $5.89B | $5.35B | $5.15B | $4.89B | $3.97B | |
| Interest Expense | $268M | $250M | $247M | $247M | $254M | $222M | $187M | $201M | $251M | $260M | $96M | $30M | |
| Interest Income | $125M | $68M | $276M | $89M | $11M | $42M | $120M | $112M | $78M | $63M | $22M | $12M | |
| Other Non-op | $-25M | $3M | $-400.0K | $10M | $6M | $-3M | $-47M | $-10M | $-15M | $-18M | $-14M | $-26M | |
| Pretax Income | $1.56B | $1.91B | $1.30B | $3.59B | $1.75B | $5.05B | $7.13B | $5.90B | $5.13B | $4.93B | $4.77B | $3.95B | |
| Income Tax | $264M | $274M | $135M | $633M | $52M | $992M | $1.16B | $1.43B | $2.46B | $1.24B | $1.16B | $990M | |
| Net Income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B | $4.43B | $2.54B | $3.70B | $3.55B | $2.93B | |
| EPS (Basic) | $8.83 | $11.21 | $8.02 | $20.96 | $10.44 | $24.86 | $31.47 | $21.63 | $11.94 | $16.96 | $15.38 | $12.42 | |
| EPS (Diluted) | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.93 | $15.34 | $12.37 | |
| Shares (Basic) | 146,500,000 | 145,600,000 | 144,700,000 | 145,300,000 | 149,100,000 | 160,900,000 | 187,100,000 | 204,900,000 | 212,600,000 | 218,400,000 | 230,700,000 | 236,400,000 | |
| Shares (Diluted) | 147,100,000 | 145,900,000 | 145,600,000 | 146,000,000 | 149,600,000 | 161,300,000 | 187,400,000 | 205,300,000 | 213,000,000 | 218,800,000 | 231,200,000 | 237,200,000 | |
| EBITDA | $780M | $673M | $495M | $518M | $3.33B | $5.01B | $7.72B | $6.91B | $6.43B | $5.83B | $5.49B | $4.66B |
Balance general 29
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | · | · | · | · | · | · | $2.91B | $1.22B | $1.57B | $2.33B | $1.31B | $1.20B | |
| Short-term Investments | · | · | · | · | · | · | $1.56B | $2.31B | $2.12B | $2.57B | $2.12B | $640M | |
| Receivables | $1.34B | $1.40B | $1.66B | $1.71B | $1.55B | $1.91B | $1.88B | $1.96B | $1.79B | $1.44B | $1.23B | $1.29B | |
| Inventory | $2.17B | $2.46B | $2.53B | $1.34B | $1.35B | $1.07B | $804M | $930M | $903M | $1.00B | $893M | $804M | |
| Other Current Assets | $1.12B | $752M | $1.18B | $1.42B | $741M | $881M | $631M | $688M | $962M | $1.09B | $837M | $310M | |
| Current Assets | $8.97B | $7.46B | $6.86B | $9.79B | $7.86B | $6.89B | $8.38B | $7.64B | $7.87B | $8.73B | $6.70B | $4.54B | |
| PP&E (Net) | $3.06B | $3.18B | $3.31B | $3.30B | $3.42B | $3.41B | $3.25B | $3.60B | $3.18B | $2.50B | $2.19B | $1.77B | |
| PP&E (Gross) | $5.99B | $5.85B | $5.71B | $5.46B | $5.42B | $5.19B | $4.84B | $5.40B | $4.74B | $3.94B | $3.52B | $2.95B | |
| Accum. Depreciation | $2.90B | $2.67B | $2.40B | $2.17B | $2.01B | $1.78B | $1.59B | $1.80B | $1.56B | $1.44B | $1.33B | $1.19B | |
| Goodwill | $6.49B | $6.48B | $6.22B | $5.75B | $5.76B | $5.76B | $5.76B | $5.71B | $4.63B | $3.67B | $2.66B | $1.76B | |
| Intangibles | $9.18B | $9.69B | $8.36B | $1.85B | $2.22B | $3.08B | $3.53B | $3.12B | $3.88B | $3.81B | $4.09B | $4.03B | |
| Other Non-current Assets | $751M | $560M | $745M | $1.53B | $1.94B | $2.90B | $1.25B | $1.69B | $432M | $1.34B | $1.11B | $755M | |
| Total Assets | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B | $27.23B | $25.29B | $23.65B | $22.88B | $19.50B | $14.31B | |
| Accounts Payable | $432M | $424M | $403M | $492M | $589M | $455M | $531M | $370M | $396M | $280M | $267M | $229M | |
| Short-term Debt | · | $1.75B | $150M | $0 | $999M | $0 | $1.50B | $0 | · | · | · | · | |
| Current Liabilities | $3.35B | $5.53B | $3.43B | $3.27B | $4.30B | $3.74B | $4.86B | $3.30B | $3.37B | $3.42B | $2.58B | $2.22B | |
| Capital Leases | $290M | $334M | $400M | $333M | $330M | $402M | $413M | $0 | · | · | · | · | |
| Deferred Tax | $508M | $190M | $642M | $335M | $694M | $1.03B | $2.81B | $1.64B | $123M | $93M | $125M | $52M | |
| Other Non-current Liabilities | $748M | $732M | $781M | $944M | $1.32B | $1.33B | $1.35B | $1.39B | $1.63B | $722M | $906M | $650M | |
| Total Liabilities | $11.18B | $11.33B | $12.05B | $11.17B | $12.92B | $13.93B | $13.90B | $12.26B | $11.05B | $10.75B | $10.13B | $3.50B | |
| Long-term Debt | $6.29B | $4.55B | $6.79B | $6.28B | $6.27B | $7.43B | $4.46B | $5.94B | $5.93B | $6.51B | $6.52B | $580M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | |
| Paid-in Capital | $863M | $569M | $302M | $73M | $68M | $0 | $0 | $0 | $98M | $0 | $0 | $4.20B | |
| Retained Earnings | $20.55B | $19.26B | $17.63B | $16.47B | $13.91B | $13.98B | $16.46B | $16.26B | $15.81B | $15.07B | $12.21B | $9.28B | |
| Treasury Stock | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.61B | $2.61B | $2.61B | |
| AOCI | $-182M | $-136M | $-154M | $-165M | $-107M | $-299M | $-135M | $-240M | $-318M | $-320M | $-224M | $-60M | |
| Stockholders' Equity | $18.26B | $16.72B | $14.80B | $13.39B | $10.96B | $10.70B | $13.34B | $13.04B | $12.61B | $12.14B | $9.37B | $10.81B | |
| Liabilities + Equity | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B | $27.23B | $25.29B | $23.65B | $22.88B | $19.50B | $14.31B | |
| Shares Outstanding | 170,500,000 | 169,500,000 | 144,900,000 | 167,900,000 | 170,800,000 | 176,200,000 | 174,200,000 | 197,200,000 | 211,500,000 | 215,900,000 | 218,600,000 | 234,600,000 |
Flujo de Efectivo 18
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $780M | $673M | $495M | $518M | $488M | $457M | $465M | $650M | $1.08B | $683M | $600M | $688M | |
| Stock-based Comp | $291M | $291M | $264M | $254M | $239M | $198M | $182M | $158M | $128M | $155M | $161M | $155M | |
| Deferred Tax | $362M | $-158M | $-306M | $-169M | $-427M | $149M | $67M | $108M | $92M | $-175M | $-146M | $-308M | |
| Amort. of Intangibles | $507M | $386M | $241M | $246M | $252M | $255M | $274M | $381M | $455M | $373M | $383M | $490M | |
| Restructuring | $49M | $30M | $219M | $131M | $0 | $0 | $2M | $12M | $900.0K | $33M | $93M | $0 | |
| Other Non-cash | $-521M | $437M | $-67M | $-2.27B | $1.78B | $-575M | $260M | $475M | $711M | $157M | $-447M | $-528M | |
| Operating Cash Flow | $2.20B | $2.88B | $1.55B | $1.38B | $3.64B | $4.23B | $7.08B | $6.19B | $4.55B | $4.59B | $3.92B | $2.94B | |
| CapEx | $154M | $154M | $277M | $240M | $258M | $425M | $514M | $771M | $867M | $616M | $643M | $288M | |
| Investing Cash Flow | $-1.37B | $-799M | $-4.10B | $1.58B | $-564M | $-609M | $470M | $-2.05B | $-2.96B | $-2.48B | $-4.55B | $-1.54B | |
| Debt Issued | $1.73B | $0 | $997M | $0 | $0 | $2.97B | $0 | $0 | · | · | · | · | |
| Net Debt Issued | $-17M | $0 | $997M | $0 | $0 | $2.97B | · | · | · | · | · | · | |
| Stock Repurchased | · | $0 | $0 | $750M | $1.80B | $6.68B | $5.87B | $4.35B | $1.37B | $1.00B | $5.00B | $887M | |
| Net Stock Activity | · | $0 | $0 | $-750M | $-1.80B | $-6.68B | $-5.87B | $-4.35B | $-1.37B | $-1.00B | $-5.00B | $-887M | |
| Financing Cash Flow | $-302M | $-684M | $149M | $-1.75B | $-2.09B | $-5.27B | $-5.86B | $-4.47B | $-2.38B | $-1.05B | $783M | $-756M | |
| Net Change in Cash | · | · | · | · | · | · | · | · | $-792M | $1.05B | $149M | $643M | |
| Taxes Paid | $864M | $355M | $741M | $933M | $248M | $907M | $1.06B | $1.01B | $1.07B | $1.64B | $1.67B | $1.16B | |
| Free Cash Flow | $2.05B | $2.72B | $1.27B | $1.14B | $3.38B | $3.81B | $6.56B | $5.42B | $3.68B | $3.91B | $3.07B | $2.65B | |
| Levered FCF | $1.83B | $2.51B | $1.05B | $941M | $3.14B | $3.63B | $6.41B | $5.26B | $3.55B | $3.71B | $3.00B | $2.63B |
Rentabilidad 8
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 86.6% | 86.4% | 86.5% | 86.7% | 87.1% | 88.5% | 87.9% | |
| Operating Margin | · | · | · | · | 25.9% | 33.8% | 49.0% | 43.8% | 43.5% | 45.0% | 45.4% | 40.9% | |
| Net Margin | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% | 29.8% | 41.0% | 32.9% | 20.7% | 32.3% | 33.0% | 30.2% | |
| Pretax Margin | 15.7% | 19.7% | 13.2% | 35.3% | 15.9% | 37.5% | 49.6% | 43.9% | 41.8% | 43.1% | 44.3% | 40.7% | |
| EBITDA Margin | 7.9% | 7.0% | 5.0% | 5.1% | 30.3% | 37.2% | 53.7% | 51.3% | 52.3% | 50.9% | 51.0% | 48.0% | |
| ROA | 4.5% | 5.9% | 4.5% | 12.6% | 6.4% | 15.4% | 22.4% | 18.1% | 10.9% | 17.5% | 21.0% | 22.4% | |
| ROE | 7.2% | 9.9% | 7.9% | 25.0% | 14.4% | 33.3% | 44.8% | 33.1% | 20.5% | 34.4% | 35.1% | 30.2% | |
| ROIC | · | · | · | · | 25.3% | 34.2% | 44.2% | 34.2% | 22.1% | 31.8% | 39.5% | 27.5% |
Liquidez y Solvencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.7 | 1.3 | 2.0 | 3.0 | 1.8 | 1.8 | 1.7 | 2.3 | 2.3 | 2.6 | 2.6 | 2.1 | |
| Quick Ratio | 0.4 | 0.3 | 0.5 | 0.5 | 0.4 | 0.5 | 1.3 | 1.7 | 1.6 | 1.9 | 1.8 | 1.4 | |
| Interest Coverage | · | · | · | · | 11.2 | 20.4 | 37.6 | 29.4 | 21.3 | 19.8 | 51.2 | 134.7 |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.7 | |
| Inventory Turnover | 1.0 | 0.9 | 1.3 | 1.7 | 1.7 | 1.9 | 2.3 | 2.0 | 1.7 | 1.6 | 1.5 | 1.6 | |
| Receivables Turnover | 7.2 | 6.3 | 5.8 | 6.3 | 6.3 | 7.1 | 7.5 | 7.2 | 7.6 | 8.6 | 8.5 | 9.2 |
Tasas de Crecimiento 9
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 2.2% | -1.6% | -3.3% | -7.4% | -18.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -0.94% | -4.1% | -9.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -6.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -21.4% | 40.3% | -61.8% | 100.7% | -58.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -25.0% | 2.4% | -31.5% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -18.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -20.8% | 40.6% | -61.9% | 95.8% | -61.1% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -24.9% | 1.6% | -33.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -20.2% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 10
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B | $10.76B | $9.70B | |
| Net Income TTM | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B | $4.43B | $2.54B | $3.70B | $3.55B | $2.93B | |
| Market Cap | $25.84B | $22.30B | $37.50B | $39.88B | $35.27B | $37.32B | $51.69B | $59.34B | $67.38B | $61.22B | $66.97B | $79.62B | |
| P/E | 20.0 | 13.7 | 32.5 | 13.3 | 23.1 | 9.9 | 9.4 | 13.9 | 26.7 | 16.8 | 20.0 | 27.4 | |
| P/S | 2.6 | 2.3 | 3.8 | 3.9 | 3.2 | 2.8 | 3.6 | 4.4 | 5.5 | 5.3 | 6.2 | 8.2 | |
| P/B | 1.4 | 1.3 | 2.5 | 3.0 | 3.2 | 3.5 | 3.9 | 4.6 | 5.3 | 5.0 | 7.1 | 7.4 | |
| P / Tangible Book | 10.0 | 40.8 | 172.6 | 6.9 | 11.8 | 20.1 | · | · | · | · | · | · | |
| P / Cash Flow | 11.7 | 7.8 | 24.2 | 28.8 | 9.7 | 8.8 | 7.3 | 9.6 | 14.8 | 13.5 | 18.0 | 27.1 | |
| P / FCF | 12.6 | 8.2 | 29.5 | 34.9 | 10.4 | 9.8 | 7.9 | 11.0 | 18.3 | 15.7 | 21.8 | 30.0 | |
| Earnings Yield | 5.0% | 7.3% | 3.1% | 7.5% | 4.3% | 10.1% | 10.6% | 7.2% | 3.7% | 6.0% | 5.0% | 3.6% |
Estado de resultados 15
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.74B | $2.48B | $2.28B | $2.53B | $2.65B | $2.43B | $2.45B | $2.47B | $2.46B | $2.29B | $2.39B | $2.53B | $2.46B | $2.46B | $2.54B | $2.51B | |
| Cost of Revenue | $777M | $661M | $496M | $674M | $605M | $629M | $584M | $639M | $546M | $542M | $618M | $660M | $593M | $663M | $571M | $470M | |
| SG&A Expense | $710M | $607M | $682M | $595M | $584M | $572M | $680M | $588M | $554M | $582M | $608M | $788M | $548M | $605M | $633M | $563M | |
| Operating Expenses | $2.60B | $2.10B | $2.34B | $1.98B | $1.90B | $2.12B | $2.16B | $2.01B | $1.77B | $1.83B | $2.09B | $2.67B | $1.75B | $2.02B | $1.94B | $1.14B | |
| Interest Expense | $82M | $68M | $68M | $67M | $73M | $60M | $60M | $60M | $61M | $69M | $72M | $64M | $49M | $62M | $55M | $60M | |
| Interest Income | $25M | $38M | $37M | $32M | $32M | $24M | $18M | $12M | $20M | $17M | $24M | $96M | $76M | $81M | $50M | $24M | |
| Other Non-op | $3M | $-1M | $-37M | $16M | $2M | $2M | $8M | $-800.0K | $-2M | $-2M | $5M | $-3M | $-2M | $600.0K | $35M | $2M | |
| Pretax Income | $132M | $378M | $-56M | $557M | $744M | $311M | $292M | $451M | $699M | $465M | $292M | $-141M | $708M | $438M | $604M | $1.37B | |
| Income Tax | $35M | $58M | $-7M | $91M | $109M | $71M | $25M | $62M | $115M | $71M | $43M | $-73M | $115M | $51M | $54M | $236M | |
| Net Income | $98M | $320M | $-49M | $466M | $635M | $240M | $267M | $388M | $584M | $393M | $250M | $-68M | $592M | $388M | $550M | $1.13B | |
| EPS (Basic) | $0.66 | $2.17 | $-0.33 | $3.18 | $4.33 | $1.65 | $1.82 | $2.67 | $4.01 | $2.71 | $1.71 | $-0.47 | $4.09 | $2.69 | $3.79 | $7.86 | |
| EPS (Diluted) | $0.66 | $2.15 | $-0.35 | $3.17 | $4.33 | $1.64 | $1.82 | $2.66 | $4.00 | $2.70 | $1.70 | $-0.47 | $4.07 | $2.67 | $3.73 | $7.84 | |
| Shares (Basic) | 147,700,000 | 147,200,000 | -292,700,000 | 146,600,000 | 146,500,000 | 146,100,000 | -290,900,000 | 145,700,000 | 145,600,000 | 145,200,000 | -289,200,000 | 144,800,000 | 144,700,000 | 144,400,000 | -292,100,000 | 144,400,000 | |
| Shares (Diluted) | 148,700,000 | 148,400,000 | -293,300,000 | 147,100,000 | 146,700,000 | 146,600,000 | -292,000,000 | 146,100,000 | 145,900,000 | 145,900,000 | -289,900,000 | 144,800,000 | 145,500,000 | 145,200,000 | -292,600,000 | 144,800,000 | |
| EBITDA | · | $204M | · | · | · | $183M | · | · | · | $148M | · | · | · | $112M | · | · |
Balance general 28
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables | · | · | $1.34B | · | · | · | $1.40B | · | · | · | · | · | · | $1.63B | · | $1.57B | |
| Inventory | $2.38B | $1.95B | $2.17B | $2.21B | $2.27B | $2.27B | $2.46B | $2.47B | $2.51B | $2.52B | · | $2.98B | $1.33B | $1.28B | · | $1.38B | |
| Other Current Assets | $1.24B | $1.17B | $1.12B | $917M | $851M | $757M | $752M | $674M | $615M | $1.17B | · | $974M | $896M | $1.41B | · | $1.50B | |
| Current Assets | $7.31B | $9.19B | $8.97B | $8.94B | $7.97B | $7.63B | $7.46B | $6.83B | $7.11B | $6.76B | · | $8.45B | $10.43B | $9.76B | · | $9.77B | |
| PP&E (Net) | $2.99B | $3.02B | $3.06B | $3.08B | $3.10B | $3.13B | $3.18B | $3.21B | $3.25B | $3.28B | · | $3.30B | $3.31B | $3.30B | · | $3.27B | |
| PP&E (Gross) | · | · | $5.99B | · | · | · | $5.85B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3.10B | $3.00B | $2.93B | $2.87B | $2.81B | $2.74B | $2.67B | $2.60B | $2.54B | $2.47B | · | $2.34B | $2.28B | $2.22B | · | $2.10B | |
| Goodwill | $6.99B | $6.49B | $6.49B | $6.49B | $6.49B | $6.48B | $6.48B | $6.49B | $6.23B | $6.23B | $6.22B | $6.81B | $5.75B | $5.75B | $5.75B | $5.74B | |
| Intangibles | $13.52B | $9.05B | $9.18B | $9.33B | $9.47B | $9.58B | $9.69B | $9.81B | $8.23B | $8.28B | · | $7.34B | $1.78B | $1.81B | · | $2.01B | |
| Other Non-current Assets | $832M | $778M | $751M | $730M | $638M | $559M | $560M | $631M | $682M | $698M | · | $755M | $1.10B | $1.38B | · | $1.61B | |
| Total Assets | $32.09B | $29.48B | $29.44B | $29.21B | $28.33B | $28.03B | $28.05B | $28.31B | $26.80B | $26.57B | · | $28.19B | $25.16B | $24.60B | · | $24.85B | |
| Accounts Payable | $404M | $358M | $432M | $413M | $408M | $392M | $424M | $423M | $354M | $387M | · | $440M | $445M | $491M | · | $383M | |
| Short-term Debt | · | · | · | $0 | $0 | $1.75B | · | $1.75B | $0 | $250M | · | $500M | · | · | · | $0 | |
| Current Liabilities | $3.92B | $3.00B | $3.35B | $3.29B | $3.18B | $5.30B | $5.53B | $5.42B | $3.11B | $3.22B | · | $5.02B | $3.19B | $3.01B | · | $3.93B | |
| Capital Leases | $265M | $273M | $290M | $305M | $311M | $323M | $334M | $357M | $368M | $406M | · | $429M | $304M | $327M | · | $355M | |
| Deferred Tax | $946M | $484M | $508M | $358M | $118M | $133M | $190M | $882M | $591M | $658M | · | $728M | $144M | $251M | · | $329M | |
| Other Non-current Liabilities | $821M | $787M | $748M | $762M | $800M | $752M | $732M | $744M | $557M | $777M | · | $748M | $777M | $936M | · | $1.20B | |
| Total Liabilities | $13.24B | $10.83B | $11.18B | $11.00B | $10.70B | $11.05B | $11.33B | $11.95B | $10.91B | $11.35B | · | $13.71B | $10.70B | $10.81B | · | $12.09B | |
| Long-term Debt | $7.29B | $6.29B | $6.29B | $6.29B | $6.28B | $4.55B | · | $4.55B | $6.29B | $6.29B | · | $6.79B | $6.28B | $6.28B | · | $6.28B | |
| Total Debt | · | · | · | $0 | $0 | $1.75B | · | $1.75B | $0 | $250M | · | $500M | · | · | · | $0 | |
| Common Stock | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Paid-in Capital | $983M | $897M | $863M | $798M | $714M | $630M | $569M | $488M | $408M | $330M | · | $242M | $171M | $91M | · | $0 | |
| Retained Earnings | $20.97B | $20.87B | $20.55B | $20.60B | $20.14B | $19.50B | $19.26B | $18.99B | $18.60B | $18.02B | · | $17.38B | $17.45B | $16.85B | · | $15.92B | |
| Treasury Stock | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | · | $2.98B | $2.98B | $2.98B | · | $2.98B | |
| AOCI | $-128M | $-140M | $-182M | $-215M | $-238M | $-174M | $-136M | $-146M | $-146M | $-160M | · | $-159M | $-173M | $-172M | · | $-164M | |
| Stockholders' Equity | $18.85B | $18.65B | $18.26B | $18.21B | $17.63B | $16.98B | $16.72B | $16.36B | $15.89B | $15.21B | $14.80B | $14.48B | $14.47B | $13.80B | $13.39B | $12.78B | |
| Liabilities + Equity | $32.09B | $29.48B | $29.44B | $29.21B | $28.33B | $28.03B | $28.05B | $28.31B | $26.80B | $26.57B | · | $28.19B | $25.16B | $24.60B | · | $24.85B | |
| Shares Outstanding | 171,500,000 | 171,400,000 | 146,800,000 | 170,500,000 | 170,400,000 | 170,300,000 | 145,800,000 | 169,500,000 | 169,500,000 | 169,400,000 | 144,900,000 | 168,700,000 | 168,600,000 | 168,600,000 | 144,000,000 | 167,800,000 |
Flujo de Efectivo 15
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $236M | $204M | $200M | $202M | $194M | $183M | $184M | $183M | $159M | $148M | $140M | $125M | $117M | $112M | $120M | $121M | |
| Stock-based Comp | $77M | $84M | $60M | $75M | $75M | $81M | $75M | $73M | $71M | $73M | $55M | $62M | $72M | $76M | $67M | $64M | |
| Deferred Tax | $-28M | $24M | $167M | $254M | $-31M | $-28M | $-58M | $-53M | $-87M | $40M | $72M | $-207M | $-106M | $-64M | $-29M | $-92M | |
| Amort. of Intangibles | $168M | · | $132M | $136M | $127M | · | $111M | $110M | $87M | · | · | · | · | · | · | · | |
| Restructuring | $165M | $8M | $7M | $7M | $-700.0K | $35M | $5M | $7M | $7M | $12M | $99M | $76M | $34M | $10M | $7M | $15M | |
| Other Non-cash | · | $14M | · | · | · | $-218M | · | · | · | $-100M | · | · | · | $-56M | · | · | |
| Operating Cash Flow | $449M | $646M | $512M | $1.27B | $161M | $259M | $761M | $936M | $626M | $553M | $12M | $592M | $487M | $455M | $-175M | $661M | |
| CapEx | $41M | $51M | $44M | $46M | $27M | $37M | $39M | $35M | $34M | $46M | $65M | $74M | $71M | $67M | $86M | $59M | |
| Investing Cash Flow | $-3.84B | $-210M | $-1.23B | $-35M | $-57M | $-47M | $-19M | $-1.18B | $466M | $-66M | $-652M | $-1.74B | $-754M | $-953M | $-141M | $1.67B | |
| Debt Issued | · | · | $0 | $-300.0K | · | · | $0 | $0 | · | · | $0 | · | · | · | $0 | · | |
| Net Debt Issued | · | · | · | · | · | $0 | · | · | · | $-400M | · | · | · | · | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | $0 | $250M | |
| Financing Cash Flow | $1.30B | $-44M | $-137M | $-130M | $-12M | $-23M | $8M | $-7M | $-245M | $-440M | $-646M | $849M | $-10M | $-43M | $-7M | $-1.25B | |
| Free Cash Flow | · | $594M | · | · | · | $222M | · | · | · | $507M | · | · | · | $389M | · | · | |
| Levered FCF | · | $537M | · | · | · | $176M | · | · | · | $449M | · | · | · | $333M | · | · |
Rentabilidad 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 3.6% | 12.9% | · | 18.4% | 24.0% | 9.9% | · | 15.8% | 23.7% | 17.2% | · | -2.7% | 24.1% | 15.8% | · | 45.2% | |
| Pretax Margin | 4.8% | 15.2% | · | 22.0% | 28.1% | 12.8% | · | 18.3% | 28.3% | 20.3% | · | -5.6% | 28.8% | 17.8% | · | 54.7% | |
| EBITDA Margin | · | 8.2% | · | · | · | 7.5% | · | · | · | 6.4% | · | · | · | 4.6% | · | · | |
| ROA | 0.32% | 1.1% | · | 1.6% | 2.3% | 0.88% | · | 1.4% | 2.2% | 1.5% | · | -0.26% | 2.4% | 1.6% | · | 4.7% | |
| ROE | 0.53% | 1.8% | · | 2.7% | 3.8% | 1.5% | · | 2.5% | 3.9% | 2.7% | · | -0.50% | 4.7% | 3.0% | · | 9.8% |
Liquidez y Solvencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 3.1 | · | 2.7 | 2.5 | 1.4 | · | 1.3 | 2.3 | 2.1 | · | 1.7 | 3.3 | 3.2 | · | 2.5 | |
| Quick Ratio | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.5 | · | 0.4 | |
| Debt / Equity | · | · | · | 0.0 | 0.0 | 0.1 | · | 0.1 | 0.0 | 0.0 | · | 0.0 | · | · | · | 0.0 |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.5 | 0.5 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | · | · | · | · | · | · | 1.5 | · | 1.5 |
Valoración (TTM) 10
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $10.39B | $10.09B | · | $10.08B | $10.01B | $9.65B | · | $9.75B | $9.74B | $9.74B | · | $9.96B | $10.02B | $10.09B | · | $10.41B | |
| Net Income TTM | $1.52B | $1.66B | · | $1.73B | $1.85B | $1.61B | · | $1.30B | $1.50B | $1.30B | · | $2.05B | $3.17B | $2.88B | · | $2.83B | |
| Market Cap | $37.05B | $31.42B | · | $23.88B | $21.40B | $23.30B | · | $32.86B | $39.29B | $36.53B | · | $43.36B | $48.03B | $46.88B | · | $44.80B | |
| P/E | 21.0 | 16.2 | · | 11.9 | 9.9 | 12.4 | · | 21.8 | 22.5 | 24.0 | · | 18.2 | 13.1 | 14.0 | · | 13.8 | |
| P/S | 3.6 | 3.1 | · | 2.4 | 2.1 | 2.4 | · | 3.4 | 4.0 | 3.8 | · | 4.4 | 4.8 | 4.6 | · | 4.3 | |
| P/B | 2.0 | 1.7 | · | 1.3 | 1.2 | 1.4 | · | 2.0 | 2.5 | 2.4 | · | 3.0 | 3.3 | 3.4 | · | 3.5 | |
| P / Tangible Book | · | 10.1 | · | 10.0 | 12.8 | 25.4 | · | 486.0 | 27.5 | 52.1 | · | 130.7 | 6.9 | 7.5 | · | 8.9 | |
| P / Cash Flow | · | 48.7 | · | · | · | 89.9 | · | · | · | 66.0 | · | · | · | 103.0 | · | · | |
| P / FCF | · | 52.9 | · | · | · | 104.9 | · | · | · | 72.0 | · | · | · | 120.6 | · | · | |
| Earnings Yield | 4.8% | 6.2% | · | 8.4% | 10.1% | 8.0% | · | 4.6% | 4.4% | 4.2% | · | 5.5% | 7.7% | 7.1% | · | 7.2% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B |
| Margen Operativo % | — | — | — | — | 25.9% |
| Beneficio neto | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| EPS Diluido | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio corriente | 2.7 | 1.3 | 2.0 | 3.0 | 1.8 |
| Ratio Rápido | 0.4 | 0.3 | 0.5 | 0.5 | 0.4 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $2.05B | $2.72B | $1.27B | $1.14B | $3.38B |
Últimas noticias Noticias recientes que mencionan a esta empresa
- What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
- Biogen avanza un fármaco para el Alzheimer a un ensayo de fase tardía a pesar de datos decepcionantes
- ¿Por qué las acciones de Biogen fueron un éxito el miércoles?
- Aquí están las principales investigaciones de analistas de Wall Street del martes: Biogen, Birkenstock, Fastly, Ford, Lennox International, Netskope, SanDisk, Tesla y más
- Por qué las acciones de Biogen se desplomaron el lunes
- Apellis Pharma se dispara por acuerdo con Biogen. ¿Es demasiado tarde para perseguir las acciones de APLS?
- Biogen adquirirá Apellis Pharmaceuticals por $5.6 mil millones, añadiendo terapias C3 a su cartera
Señales de trading Señales recientes de compra/venta con precio de entrada y ratio riesgo/recompensa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 1 151 declarantes · $23.5B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 133 (-29 vs trimestre anterior) | 76 (-23 vs trimestre anterior) | 406 (+25 vs trimestre anterior) | 295 (-2 vs trimestre anterior) | +24.3M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | $3 274 304 389 | 15 154 606 | 13,93% | Acciones |
| VANGUARD GROUP INC | $2 812 686 259 | 15 982 080 | 11,97% | Acciones |
| FMR LLC | $2 480 996 199 | 11 482 904 | 10,56% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $2 085 220 339 | 9 651 117 | 8,87% | Acciones |
| STATE STREET CORP | $1 586 815 292 | 7 344 327 | 6,75% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1 427 062 472 | 6 604 936 | 6,07% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $853 425 885 | 3 965 587 | 3,63% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $651 741 965 | 3 016 486 | 2,77% | Acciones |
| NORGES BANK | $557 441 930 | 2 580 033 | 2,37% | Acciones |
| Boston Partners | $237 039 714 | 1 097 693 | 1,01% | Acciones |
| Alyeska Investment Group, L.P. | $201 448 726 | 932 374 | 0,86% | Acciones |
| Pictet Asset Management Holding SA | $184 144 886 | 851 819 | 0,78% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $183 196 029 | 847 893 | 0,78% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $179 182 447 | 829 318 | 0,76% | Acciones |
| Robeco Institutional Asset Management B.V. | $170 923 341 | 791 092 | 0,73% | Acciones |
| FRED ALGER MANAGEMENT, LLC | $170 321 610 | 788 307 | 0,72% | Acciones |
| BANK OF AMERICA CORP /DE/ | $156 665 322 | 725 101 | 0,67% | Acciones |
| Employees Provident Fund Board | $152 148 588 | 704 196 | 0,65% | Acciones |
| FIRST TRUST ADVISORS LP | $147 357 277 | 682 021 | 0,63% | Acciones |
| AustralianSuper Pty Ltd | $145 348 531 | 672 723 | 0,62% | Acciones |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $129 114 863 | 597 588 | 0,55% | Acciones |
| BlackRock, Inc. | $124 065 973 | 574 220 | 0,53% | Acciones |
| Artemis Investment Management LLP | $123 364 642 | 570 974 | 0,52% | Acciones |
| Legal & General Group Plc | $119 267 279 | 552 010 | 0,51% | Acciones |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $116 672 616 | 540 001 | 0,50% | Acciones |
| Caisse de depot et placement du Quebec | $110 232 516 | 510 194 | 0,47% | Acciones |
| UBS Group AG | $108 289 272 | 501 200 | 0,46% | Opción de compra |
| CITADEL ADVISORS LLC | $90 389 997 | 418 356 | 0,38% | Acciones |
| Swiss National Bank | $89 427 234 | 413 900 | 0,38% | Acciones |
| National Pension Service | $87 734 188 | 406 064 | 0,37% | Acciones |
| LMR Partners LLP | $84 047 340 | 389 000 | 0,36% | Opción de compra |
| BNP PARIBAS FINANCIAL MARKETS | $83 732 325 | 387 542 | 0,36% | Acciones |
| Candriam S.C.A. | $82 957 583 | 384 326 | 0,35% | Acciones |
| ROYAL BANK OF CANADA | $78 304 000 | 362 418 | 0,33% | Acciones |
| Mitsubishi UFJ Asset Management Co., Ltd. | $77 527 297 | 358 823 | 0,33% | Acciones |
| Sumitomo Mitsui Trust Group, Inc. | $74 890 069 | 346 617 | 0,32% | Acciones |
| VICTORY CAPITAL MANAGEMENT INC | $74 199 109 | 343 419 | 0,32% | Acciones |
| Fisher Asset Management, LLC | $73 032 374 | 338 018 | 0,31% | Acciones |
| Vanguard Global Advisers, LLC | $72 582 332 | 335 936 | 0,31% | Acciones |
| California Public Employees Retirement System | $71 106 642 | 329 106 | 0,30% | Acciones |
| Swedbank AB | $69 271 861 | 320 614 | 0,29% | Acciones |
| CITADEL ADVISORS LLC | $68 058 900 | 315 000 | 0,29% | Opción de compra |
| GOLDMAN SACHS GROUP INC | $63 917 486 | 295 832 | 0,27% | Acciones |
| LMR Partners LLP | $62 268 492 | 288 200 | 0,26% | Opción de venta |
| VANGUARD ASSET MANAGEMENT, Ltd | $61 442 279 | 284 376 | 0,26% | Acciones |
| Patient Capital Management, LLC | $61 295 674 | 283 697 | 0,26% | Acciones |
| Gotham Asset Management, LLC | $60 475 194 | 279 900 | 0,26% | Acciones |
| CAUSEWAY CAPITAL MANAGEMENT LLC | $60 125 780 | 278 283 | 0,26% | Acciones |
| PERCEPTIVE ADVISORS LLC | $59 669 938 | 276 173 | 0,25% | Acciones |
| Balyasny Asset Management L.P. | $57 275 345 | 265 090 | 0,24% | Acciones |
| RHUMBLINE ADVISERS | $56 819 153 | 262 979 | 0,24% | Acciones |
| HSBC HOLDINGS PLC | $52 886 951 | 244 779 | 0,23% | Acciones |
| AEGON ASSET MANAGEMENT UK Plc | $52 092 282 | 241 101 | 0,22% | Acciones |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $47 304 392 | 218 941 | 0,20% | Acciones |
| JANE STREET GROUP, LLC | $47 122 686 | 218 100 | 0,20% | Opción de venta |
| KLP KAPITALFORVALTNING AS | $43 034 183 | 199 177 | 0,18% | Acciones |
| JANE STREET GROUP, LLC | $41 289 066 | 191 100 | 0,18% | Opción de compra |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $40 458 548 | 220 687 | 0,17% | Acciones |
| PANAGORA ASSET MANAGEMENT INC | $40 387 880 | 186 929 | 0,17% | Acciones |
| NISSAY ASSET MANAGEMENT CORP /JAPAN | $40 036 134 | 185 301 | 0,17% | Acciones |
| PRINCIPAL FINANCIAL GROUP INC | $39 509 594 | 182 864 | 0,17% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $39 411 367 | 214 975 | 0,17% | Acciones |
| BARCLAYS PLC | $38 890 800 | 180 000 | 0,17% | Opción de venta |
| BARCLAYS PLC | $37 038 518 | 171 427 | 0,16% | Acciones |
| Quantinno Capital Management LP | $32 836 341 | 151 977 | 0,14% | Acciones |
| MORGAN STANLEY | $32 548 902 | 150 647 | 0,14% | Acciones |
| LETKO, BROSSEAU & ASSOCIATES INC | $31 666 186 | 146 562 | 0,13% | Acciones |
| Portolan Capital Management, LLC | $30 865 467 | 142 856 | 0,13% | Acciones |
| Palo Alto Investors LP | $30 308 681 | 140 279 | 0,13% | Acciones |
| Walleye Trading LLC | $30 087 003 | 139 253 | 0,13% | Acciones |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $29 872 456 | 138 260 | 0,13% | Acciones |
| Nippon Life Global Investors Americas, Inc. | $29 647 753 | 137 220 | 0,13% | Acciones |
| CITADEL ADVISORS LLC | $28 995 252 | 134 200 | 0,12% | Opción de venta |
| IEQ CAPITAL, LLC | $28 550 680 | 132 142 | 0,12% | Acciones |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $28 001 160 | 129 599 | 0,12% | Acciones |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $26 210 455 | 121 311 | 0,11% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $24 663 681 | 114 152 | 0,10% | Acciones |
| Woodline Partners LP | $24 298 756 | 112 463 | 0,10% | Acciones |
| AVIVA PLC | $23 345 715 | 108 052 | 0,10% | Acciones |
| Eurizon Capital SGR S.p.A. | $22 171 682 | 102 594 | 0,09% | Acciones |
| ADAMS DIVERSIFIED EQUITY FUND, INC. | $21 670 818 | 100 300 | 0,09% | Acciones |
| NEW YORK STATE COMMON RETIREMENT FUND | $21 637 329 | 100 145 | 0,09% | Acciones |
| UBS Group AG | $21 607 945 | 100 009 | 0,09% | Acciones |
| SPHERA FUNDS MANAGEMENT LTD. | $21 606 000 | 100 000 | 0,09% | Opción de compra |
| Balyasny Asset Management L.P. | $21 606 000 | 100 000 | 0,09% | Opción de compra |
| Integral Health Asset Management, LLC | $21 606 000 | 100 000 | 0,09% | Acciones |
| Illinois Municipal Retirement Fund | $21 455 406 | 99 303 | 0,09% | Acciones |
| Susquehanna Portfolio Strategies, LLC | $21 346 944 | 98 801 | 0,09% | Acciones |
| APG Asset Management N.V. | $20 973 675 | 110 984 | 0,09% | Acciones |
| SPHERA FUNDS MANAGEMENT LTD. | $20 877 014 | 96 626 | 0,09% | Acciones |
| LPL Financial LLC | $20 626 314 | 95 466 | 0,09% | Acciones |
| Rhenman & Partners Asset Management AB | $20 493 291 | 94 850 | 0,09% | Acciones |
| PEAK6 LLC | $20 374 458 | 94 300 | 0,09% | Opción de compra |
| STRS OHIO | $20 265 132 | 93 794 | 0,09% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $19 614 791 | 90 784 | 0,08% | Acciones |
| Hudson Bay Capital Management LP | $19 445 400 | 90 000 | 0,08% | Acciones |
| VAN ECK ASSOCIATES CORP | $19 191 313 | 88 824 | 0,08% | Acciones |
| Point72 Asset Management, L.P. | $19 045 473 | 88 149 | 0,08% | Acciones |
| ANTIPODES PARTNERS Ltd | $18 759 842 | 86 827 | 0,08% | Acciones |
| MACKENZIE FINANCIAL CORP | $18 666 288 | 86 394 | 0,08% | Acciones |
Informantes de la empresa 83 insiders · 51 directivos · 28 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Christopher Viehbacher | President and CEO | 13 de febrero de 2026 A | 29 924 | 0 | 0 | $0 |
| Michel Vounatsos | Chief Executive Officer | 18 de febrero de 2022 J | 67 261 | 0 | 0 | $0 |
| George A Scangos | Chief Executive Officer | 21 de julio de 2016 S | 54 779 | 0 | 0 | $0 |
| MULLEN JAMES C | CEO & President | 8 de junio de 2010 A | 95 503 | 0 | 0 | $0 |
| Robin Kramer | Chief Financial Officer | 13 de febrero de 2026 A | 11 472 | 0 | 0 | $0 |
| Michael R. Mcdonnell | EVP, Chief Financial Officer | 10 de febrero de 2025 M | 24 341 | 0 | 0 | $0 |
| Jeffrey D Capello | EVP & Chief Financial Officer | 12 de febrero de 2020 J | 3 118 | 0 | 0 | $0 |
| Paul J Clancy | Executive VP and CFO | 25 de abril de 2017 S | 10 813 | 0 | 0 | $0 |
| KELLOGG PETER N | EVP, Finance and CFO | 20 de marzo de 2007 S | 18 966 | 0 | 0 | $0 |
| Robert A Hamm | Chief Operating Officer | 23 de abril de 2010 S | 27 212 | 0 | 0 | $0 |
| HASLER HANS PETER | Chief Operating Officer | 24 de febrero de 2009 A | 53 261 | 0 | 0 | $0 |
| William R Rohn | Chief Operating Officer | 17 de noviembre de 2004 M | 65 462 | 0 | 0 | $0 |
| Adam Keeney | Head of Corporate Development | 1 de mayo de 2026 M | 6 365 | 0 | 0 | $0 |
| Sean Godbout | Chief Accounting Officer | 1 de abril de 2026 M | 1 342 | 0 | 0 | $0 |
| Jane Grogan | Head of Research | 13 de febrero de 2026 A | 4 058 | 0 | 0 | $0 |
| Nicole Murphy | Head of Pharm Ops and Tech | 13 de febrero de 2026 A | 19 611 | 1 | 0 | $585 |
| Rachid Izzar | Head of Global Product Strat. | 13 de febrero de 2026 A | 11 011 | 0 | 0 | $0 |
| Singhal Priya | Head of Development | 13 de febrero de 2026 A | 8 043 | 0 | 3 | $-734 709 |
| Ginger Gregory | EVP, Human Resources | 13 de febrero de 2026 A | 22 359 | 0 | 0 | $0 |
| Susan H Alexander | EVP Chief Legal Officer | 13 de febrero de 2026 A | 41 807 | 0 | 0 | $0 |
| Chirfi Guindo | Head of Glob Prod Strat & Com | 18 de febrero de 2022 J | 7 364 | 0 | 0 | $0 |
| Alphonse Galdes | EVP Pharmaceutical Oper & Tech | 19 de enero de 2022 A | 5 064 | 0 | 0 | $0 |
| Alfred Sandrock | Head of Research & Development | 7 de junio de 2021 S | 10 169 | 0 | 0 | $0 |
| Daniel Karp | EVP, Corporate Development | 12 de febrero de 2020 A | 930 | 0 | 0 | $0 |
| Michael D Ehlers | EVP, Research and Development | 1 de junio de 2019 J | 8 025 | 0 | 0 | $0 |
| Paul Mckenzie | EVP Pharmaceutical Oper & Tech | 1 de marzo de 2019 J | 7 235 | 0 | 0 | $0 |
| Gregory F Covino | VP, Chief Accounting Officer | 1 de marzo de 2018 A | 4 744 | 0 | 0 | $0 |
| Jean-Paul Kress | EVP Pres Int'l & Global Hd GTO | 3 de julio de 2017 A | — | 0 | 0 | $0 |
| Adriana Karaboutis | EVP, Tech, Bus. Sol & Corp Aff | 28 de febrero de 2017 M | 8 752 | 0 | 0 | $0 |
| Kenneth Dipietro | EVP Human Resources | 28 de febrero de 2017 J | 7 177 | 0 | 0 | $0 |
| Adam Koppel | EVP, Strategy and Bus. Dev. | 6 de junio de 2016 S | 2 402 | 0 | 0 | $0 |
| Spyridon Artavanis-Tsakonas | EVP, Chief Scientific Officer | 2 de abril de 2016 M | 3 150 | 0 | 0 | $0 |
| John Cox | EVP Pharmaceutical Oper & Tech | 1 de abril de 2016 A | 39 045 | 0 | 0 | $0 |
| Steven H Holtzman | EVP Corporate Development | 23 de febrero de 2016 J | 8 326 | 0 | 0 | $0 |
| Douglas E Williams | EVP Research & Development | 19 de junio de 2015 S | 11 817 | 0 | 0 | $0 |
| Stuart A Kingsley | EVP, Global Comm. Operations | 23 de febrero de 2015 A | 8 132 | 0 | 0 | $0 |
| Raymond Pawlicki | SVP, Chief Information Officer | 22 de noviembre de 2013 M | 8 710 | 0 | 0 | $0 |
| Robert E. Gagnon | Vice President, Finance | 29 de febrero de 2012 S | 3 999 | 0 | 0 | $0 |
| Francesco Granata | EVP Global Commercial Operatio | 1 de febrero de 2012 M | 3 529 | 0 | 0 | $0 |
| SCHNEIER CRAIG ERIC | EVP, HR, Public Affairs & Comm | 1 de marzo de 2011 M | 10 201 | 0 | 0 | $0 |
| Michael F Maclean | SVP, Chief Accounting Officer | 1 de octubre de 2010 F | 10 681 | 0 | 0 | $0 |
| Michael Lytton | EVP Corporate & Business Devel | 2 de marzo de 2010 F | 18 869 | 0 | 0 | $0 |
| Mark C Wiggins | EVP Corp. and Bus. Dev. | 26 de septiembre de 2008 S | 22 780 | 0 | 0 | $0 |
| Faheem Hasnain | EVP, Oncology/Rheumatology SBU | 9 de julio de 2008 M | 25 454 | 0 | 0 | $0 |
| ADELMAN BURT A | EVP, Portfolio Strategy | 15 de octubre de 2007 M | 12 769 | 0 | 0 | $0 |
| Michael Kowolenko | SVP, Pharm Ops & Technology | 25 de julio de 2007 M | 18 124 | 0 | 0 | $0 |
| Connie Matsui | EVP, Corp. Strategy and Comm. | 12 de febrero de 2007 A | 22 837 | 0 | 0 | $0 |
| William H Rastetter | Executive Chairman | 23 de febrero de 2005 J | 373 929 | 0 | 0 | $0 |
| Michael Gilman | EVP - Research | 17 de febrero de 2005 A | 23 000 | 0 | 0 | $0 |
| BUCKNUM THOMAS J | EVP and General Counsel | 17 de febrero de 2005 A | 5 750 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 7 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Biogen Inc. ×8 presentaciones | 14 de mayo de 2026 | 0,00% | Enmienda | M&A / venta | SEC |
| High River Limited Partnership, Hopper Investments LLC, Barberry Corp., Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP, Icahn Partners Master Fund III LP, Icahn Offshore LP, Icahn Partners LP, Icahn Onshore LP, Icahn Capital LP, IPH GP LLC, Icahn Enterprises Holdings L.P., Icahn Enterprises G.P. Inc., Beckton Corp., Carl C. Icahn ×4 presentaciones | 22 de junio de 2011 | — | Presentación inicial | — | SEC |
| 22 de marzo de 2010 | — | Presentación inicial | — | SEC | |
| Persona informante no revelada, Persona informante no revelada, Persona informante no revelada, Persona informante no revelada, Persona informante no revelada | 28 de enero de 2010 | — | Presentación inicial | — | SEC |
| AND | 8 de mayo de 2008 | — | Presentación inicial | — | SEC |
| Biogen Idec Inc., Biogen Idec MA Inc. ×3 presentaciones | 9 de noviembre de 2006 | — | Presentación inicial | M&A / venta | SEC |
| Persona informante no revelada, Persona informante no revelada | 14 de febrero de 2001 | — | Presentación inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 199 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 4,72% | 82 332 SH | 8 de agosto de 2026 | Diario |
| IBRN · iShares Trust | 4,02% | 1 505 SH | 8 de agosto de 2026 | Diario |
| PJP · Invesco Exchange-Traded Fund Trust | 2,74% | 66 627 SH | 8 de agosto de 2026 | Diario |
| IBB · iShares Trust | 2,33% | 1 074 761 SH | 8 de agosto de 2026 | Diario |
| FXH · First Trust Exchange-Traded AlphaDE… | 2,23% | 103 216 NS | 30 de abril de 2026 | N-PORT |
| SPIT · RBB Fund, Inc. | 2,11% | 3 185 NS | 30 de abril de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 2,09% | 8 035 SH | 8 de agosto de 2026 | Diario |
| BBP · ETFis Series Trust I | 1,73% | 5 434 NS | 30 de abril de 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,62% | 61 078 SH | 8 de agosto de 2026 | Diario |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 1,48% | 84 204 SH | 8 de agosto de 2026 | Diario |
| BIB · ProShares Trust | 1,44% | 5 425 NS | 31 de mayo de 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 1,39% | 2 280 NS | 31 de mayo de 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 1,34% | 2 744 NS | 30 de abril de 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1,30% | 764 NS | 30 de abril de 2026 | N-PORT |
| NUMV · Nushares ETF Trust | 1,01% | 23 096 NS | 30 de abril de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,93% | 25 484 NS | 30 de abril de 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,88% | 5 573 SH | 8 de agosto de 2026 | Diario |
| ABCS · EA Series Trust | 0,75% | 431 NS | 29 de mayo de 2026 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 0,74% | 6 263 NS | 30 de abril de 2026 | N-PORT |
| FLRG · FIDELITY COVINGTON TRUST | 0,73% | 10 857 NS | 30 de abril de 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,72% | 49 392 NS | 30 de abril de 2026 | N-PORT |
| AVMV · AMERICAN CENTURY ETF TRUST | 0,70% | 22 249 NS | 31 de mayo de 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,69% | 558 NS | 30 de abril de 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,67% | 642 650 NS | 30 de abril de 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,66% | 1 636 NS | 30 de abril de 2026 | N-PORT |
| ITAN · EA Series Trust | 0,59% | 2 701 NS | 29 de mayo de 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,58% | 18 519 NS | 30 de abril de 2026 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0,55% | 948 376 SH | 8 de agosto de 2026 | Diario |
| IYH · iShares Trust | 0,50% | 88 325 SH | 8 de agosto de 2026 | Diario |
| RCGE · EA Series Trust | 0,48% | 2 389 NS | 30 de abril de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,47% | 441 144 SH | 8 de agosto de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,45% | 67 622 NS | 30 de abril de 2026 | N-PORT |
| RPV · Invesco Exchange-Traded Fund Trust | 0,43% | 35 530 SH | 8 de agosto de 2026 | Diario |
| IMCV · iShares Trust | 0,42% | 23 383 SH | 8 de agosto de 2026 | Diario |
| RXL · ProShares Trust | 0,42% | 1 530 NS | 31 de mayo de 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,40% | 2 927 NS | 30 de abril de 2026 | N-PORT |
| IXJ · iShares Trust | 0,38% | 77 453 SH | 8 de agosto de 2026 | Diario |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,37% | 10 761 000 | 8 de agosto de 2026 | Diario |
| FAB · First Trust Exchange-Traded AlphaDE… | 0,36% | 2 605 NS | 30 de abril de 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,35% | 7 256 NS | 31 de mayo de 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,34% | 26 804 NS | 30 de abril de 2026 | N-PORT |
| VLUE · iShares Trust | 0,33% | 149 494 SH | 8 de agosto de 2026 | Diario |
| VO · VANGUARD INDEX FUNDS | 0,31% | 3 199 564 SH | 8 de agosto de 2026 | Diario |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,29% | 6 727 NS | 30 de abril de 2026 | N-PORT |
| IWS · iShares Trust | 0,29% | 222 364 SH | 8 de agosto de 2026 | Diario |
| GINN · Goldman Sachs ETF Trust | 0,27% | 2 960 NS | 31 de mayo de 2026 | N-PORT |
| FLCV · Federated Hermes ETF Trust | 0,27% | 1 332 NS | 31 de mayo de 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,26% | 8 169 NS | 31 de mayo de 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,26% | 8 407 SH | 8 de agosto de 2026 | Diario |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,26% | 136 NS | 31 de mayo de 2026 | N-PORT |